≡

CLIA Kit for Insulin Like Growth Factor Binding Protein 7 (IGFBP7)

FSTL2; IGFBP-7v; MAC25; PSF; TAF; IGFBP-rP1; MAC25 protein; Prostacyclin-stimulating factor; PGI2-stimulating factor; Tumor-derived adhesion factor

Specificity

This assay has high sensitivity and excellent specificity for detection of Insulin Like Growth Factor Binding Protein 7 (IGFBP7).
No significant cross-reactivity or interference between Insulin Like Growth Factor Binding Protein 7 (IGFBP7) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Insulin Like Growth Factor Binding Protein 7 (IGFBP7) and the recovery rates were calculated by comparing the measured value to the expected amount of Insulin Like Growth Factor Binding Protein 7 (IGFBP7) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 79-94 88
EDTA plasma(n=5) 86-93 90
heparin plasma(n=5) 78-90 85

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Insulin Like Growth Factor Binding Protein 7 (IGFBP7) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Insulin Like Growth Factor Binding Protein 7 (IGFBP7) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Insulin Like Growth Factor Binding Protein 7 (IGFBP7) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 95-102% 87-101% 93-101% 94-105%
EDTA plasma(n=5) 84-101% 82-99% 83-101% 80-89%
heparin plasma(n=5) 89-104% 84-98% 82-96% 96-104%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
Pre-coated, ready to use 96-well strip plate 1 Plate sealer for 96 wells 4
Standard 2 Standard Diluent 1×20mL
Detection Reagent A 1×120µL Assay Diluent A 1×12mL
Detection Reagent B 1×120µL Assay Diluent B 1×12mL
Substrate A 1×10mL Substrate B 1×2mL
Wash Buffer (30 × concentrate) 1×20mL Instruction manual 1

Assay procedure summary

1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 100µL Substrate Solution. Incubate 10 minutes at 37°C;
8. Read RLU value immediately.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
PLoS One Role of IGFBP7 in Diabetic Nephropathy: TGF-β1 Induces IGFBP7 via Smad2/4 in Human Renal Proximal Tubular Epithelial Cells Pubmed:26974954
PLOS ONE Role of IGFBP7 in Diabetic Nephropathy: TGF-β1 Induces IGFBP7 via Smad2/4 in Human Renal Proximal Tubular Epithelial Cells. pubmed:26974954
Journal of Alzheimers Disease Urine-Based Biomarkers for Alzheimer's Disease Identified Through Coupling Computational and Experimental Methods Pubmed:30040720
Cancers (Basel). IGFBP7 Drives Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition in Lung Cancer Pubmed: 30609749
Advances in Medical Sciences Insulin-like growth factor-binding protein 7 (IGFBP 7) as a new biomarker in coronary heart disease Pubmed: 30769262
PLoS One Altered insulin-like growth factor-2 signaling is associated with psychopathology and cognitive deficits in patients with schizophrenia Pubmed: 32191705
Scientific reports Discovery of novel biomarkers for atherosclerotic aortic aneurysm through proteomics-based assessment of disease progression Pubmed: 32286426
Genet Med SNORD116 and growth hormone therapy impact IGFBP7 in Prader¨CWilli syndrome 34040195
Sci Rep Biomarkers of persistent renal vulnerability after acute kidney injury recovery 34707157
Biomolecules IGFBP7 Concentration May Reflect Subclinical Myocardial Damage and Kidney Function in Patients with Stable Ischemic Heart Disease Pubmed:35204773
Biomolecules Insulin-Like Growth Factor-Binding Protein 7 (IGFBP-7)—New Diagnostic and Prognostic Marker in Symptomatic Peripheral Arterial Disease?—Pilot Study Pubmed:35625639
Catalog No. Related products for research use of Homo sapiens (Human) Organism species Applications (RESEARCH USE ONLY!)
RPB673Hu01 Recombinant Insulin Like Growth Factor Binding Protein 7 (IGFBP7) Positive Control; Immunogen; SDS-PAGE; WB.
RPB673Hu03 Recombinant Insulin Like Growth Factor Binding Protein 7 (IGFBP7) Positive Control; Immunogen; SDS-PAGE; WB.
RPB673Hu02 Recombinant Insulin Like Growth Factor Binding Protein 7 (IGFBP7) Positive Control; Immunogen; SDS-PAGE; WB.
PAB673Hu01 Polyclonal Antibody to Insulin Like Growth Factor Binding Protein 7 (IGFBP7) WB; IHC; ICC; IP.
MAB673Hu22 Monoclonal Antibody to Insulin Like Growth Factor Binding Protein 7 (IGFBP7) WB; IHC; ICC; IP.
SEB673Hu ELISA Kit for Insulin Like Growth Factor Binding Protein 7 (IGFBP7) Enzyme-linked immunosorbent assay for Antigen Detection.
SCB673Hu CLIA Kit for Insulin Like Growth Factor Binding Protein 7 (IGFBP7) Chemiluminescent immunoassay for Antigen Detection.
LMB673Hu Multiplex Assay Kit for Insulin Like Growth Factor Binding Protein 7 (IGFBP7) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.